Article,

Targeting interleukin-4 to the arthritic joint

, , , , , , , , , , , , and .
J Control Release, (2020)Spieler, Valerie Ludwig, Marie-Gabrielle Dawson, Janet Tigani, Bruno Littlewood-Evans, Amanda Safina, Caterina Ebersbach, Hilmar Seuwen, Klaus Raschig, Martina Ter Mors, Bjorn Muller, Thomas D Meinel, Lorenz Luhmann, Tessa eng Research Support, Non-U.S. Gov't Netherlands 2020/07/13 J Control Release. 2020 Oct 10;326:172-180. doi: 10.1016/j.jconrel.2020.07.005. Epub 2020 Jul 10..
DOI: 10.1016/j.jconrel.2020.07.005

Abstract

Anti-inflammatory cytokines are a promising class of therapeutics for treatment of rheumatoid arthritis (RA), but their use is currently limited by a rapid clearance and systemic toxicity. Interleukin-4 is a small cytokine with potential for RA therapy. To increase its pharmacokinetic features, we engineered a murine IL4 conjugate by incorporating an unnatural amino acid through genetic code expansion to which PEG-folate, as a targeting moiety and PEG alone as control, were site-specifically bound. Both IL4 conjugates retained bioactivity and induced primary murine macrophage polarization into an alternatively activated (M2) related phenotype. The PEGylated conjugates had a terminal half-life of about four hours in healthy mice compared to unPEGylated IL4 (0.76 h). We showed that both conjugates successfully accumulated into arthritic joints in an antigen-induced arthritis (AIA) mouse model, as assessed by non-invasive fluorescence imaging. The modular nature of the IL4 conjugate chemistry presented herein facilitates easy adaption of PEG chain length and targeting moieties for further improvement of half-life and targeting function for future efficacy studies.

Tags

Users

  • @jvsi_all

Comments and Reviews